Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$7.16
+3.8%
$7.76
$4.64
$61.90
$87.64M3.12342,677 shs274,774 shs
CervoMed Inc. stock logo
CRVO
CervoMed
$5.93
-5.6%
$8.12
$1.80
$20.63
$51.59M-0.731.33 million shs155,394 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.26
-0.6%
$3.24
$2.57
$6.88
$20.15M0.639,073 shs1,157 shs
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$1.43
-1.4%
$1.50
$1.02
$7.89
$80.92M0.98412,223 shs294,957 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-6.76%-12.55%-5.61%+37.18%-84.75%
CervoMed Inc. stock logo
CRVO
CervoMed
+3.80%-3.68%-11.67%-37.07%-63.32%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+1.86%-1.50%-2.24%-6.82%-45.51%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
+3.57%0.00%+1.05%+14.17%-75.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.955 of 5 stars
3.60.00.04.72.02.50.6
CervoMed Inc. stock logo
CRVO
CervoMed
3.2385 of 5 stars
3.44.00.00.03.31.70.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.1247 of 5 stars
0.03.00.00.03.11.70.6
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
2.9029 of 5 stars
3.51.00.00.03.33.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.10
Buy$50.88610.54% Upside
CervoMed Inc. stock logo
CRVO
CervoMed
2.89
Moderate Buy$27.63365.85% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3.00
Buy$7.80445.45% Upside

Current Analyst Ratings Breakdown

Latest NAII, CRVO, CRBP, and TCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/13/2025
CervoMed Inc. stock logo
CRVO
CervoMed
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/12/2025
CervoMed Inc. stock logo
CRVO
CervoMed
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$14.00 ➝ $15.00
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$65.00 ➝ $58.00
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $56.00
5/7/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $40.00
5/7/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
5/6/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$7.00
4/8/2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$11.69 per shareN/A
CervoMed Inc. stock logo
CRVO
CervoMed
$9.74M5.30N/AN/A$4.50 per share1.32
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.18N/AN/A$13.32 per share0.24
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
$2.82M28.70N/AN/A$4.26 per share0.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$40.21M-$4.22N/AN/AN/AN/A-36.87%-32.87%8/5/2025 (Estimated)
CervoMed Inc. stock logo
CRVO
CervoMed
-$16.29M-$2.18N/AN/AN/A-200.57%-44.07%-40.65%8/8/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$127.50M-$1.09N/AN/AN/A-2,974.08%-55.76%-36.56%8/11/2025 (Estimated)

Latest NAII, CRVO, CRBP, and TCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
CervoMed Inc. stock logo
CRVO
CervoMed
-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million
5/12/2025Q1 2025
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
-$0.28-$0.26+$0.02-$0.26$1.62 million$2.17 million
5/6/2025Q1 2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.26-$1.39-$0.13-$1.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
CervoMed Inc. stock logo
CRVO
CervoMed
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
11.82
11.82
CervoMed Inc. stock logo
CRVO
CervoMed
N/A
9.78
9.78
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
0.15
8.55
8.55

Institutional Ownership

CompanyInstitutional Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
CervoMed Inc. stock logo
CRVO
CervoMed
25.15%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
82.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4012.24 million11.75 millionOptionable
CervoMed Inc. stock logo
CRVO
CervoMed
48.70 million5.62 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
10056.59 million54.13 millionNot Optionable

Recent News About These Companies

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)
TScan Therapeutics appoints Camiolo as SVP, Market Access
TScan Therapeutics assumed with an Overweight at Morgan Stanley

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$7.16 +0.26 (+3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$7.19 +0.03 (+0.42%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CervoMed stock logo

CervoMed NASDAQ:CRVO

$5.93 -0.35 (-5.57%)
Closing price 04:00 PM Eastern
Extended Trading
$5.97 +0.04 (+0.61%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.28 +0.01 (+0.15%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

TScan Therapeutics stock logo

TScan Therapeutics NASDAQ:TCRX

$1.43 -0.02 (-1.38%)
Closing price 04:00 PM Eastern
Extended Trading
$1.44 +0.01 (+0.35%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.